What Are iPSCs? The Future of Regenerative Medicine Explained

Induced pluripotent stem cells (iPSCs) are adult cells, like skin or blood cells, that are reprogrammed to behave like embryonic stem cells. This process uses "Yamanaka factors" (Oct4, Sox2, Klf4, and c-Myc) to erase the cell's identity, making it pluripotent - able to transform into almost any cell type in the body. Since their discovery in 2006, iPSCs have revolutionized medicine by offering personalized treatments, disease modeling, and tissue repair without the ethical concerns of embryonic stem cells.

Key takeaways:

• iPSCs are derived from adult cells, avoiding embryo destruction.
• They can develop into over 200 cell types, reducing immune rejection risks when used for personalized medicine.
• Recent advancements include treating diabetes, Parkinson's disease, and corneal disorders with iPSC-based therapies.
• Cord blood banking is a promising way to preserve cells for future iPSC applications.

iPSCs are reshaping medicine, offering safer and more tailored treatments for conditions once considered untreatable.

How iPSCs Are Created

Understanding Yamanaka Factors

Transforming an adult cell into an iPSC involves a process called reprogramming, which hinges on four key genes known as Yamanaka factors: Oct4, Sox2, Klf4, and c-Myc (often abbreviated as OSKM). These genes act as molecular switches, effectively turning off the genes responsible for a cell's specialized function - like being a skin cell - and activating the genes linked to pluripotency.

To introduce these factors into adult cells, scientists use delivery methods called vectors. These vectors can include modified viruses, plasmids (circular DNA molecules), or synthetic mRNA. Once inside the cell, the Yamanaka factors reorganize the cell's DNA, loosening its tightly packed structure and removing chemical markers that suppress pluripotency. The reprogramming process typically unfolds over 3–4 weeks and occurs in two stages: an initial random phase followed by a phase where the cell commits to its new pluripotent identity.

Interestingly, the success rate of this transformation is quite low - only about 0.01% to 0.1% of cells make it through the full reprogramming process. Despite this, the groundbreaking discovery by Dr. Shinya Yamanaka and Kazutoshi Takahashi in 2006 proved that cellular specialization is reversible. This work earned Yamanaka the Nobel Prize in Physiology or Medicine in 2012, just six years after the discovery.

One notable example of iPSC technology in action occurred in September 2014. A team led by Masayo Takahashi at the RIKEN Center for Developmental Biology conducted the first-ever clinical transplant using iPSCs. They reprogrammed skin cells from a 70-year-old woman with wet age-related macular degeneration into retinal pigment epithelial cells. These lab-grown cells were transplanted into her eye, leading to improved vision without any signs of immune rejection or tumor formation after one year.

This reprogramming process highlights the unique potential of iPSCs, especially when compared to other types of stem cells.

iPSCs vs. Other Stem Cell Types

The reprogramming process not only showcases scientific progress but also underscores the distinct benefits of iPSCs compared to other stem cell types.

What sets iPSCs apart is how they are created and their ethical advantages. Unlike embryonic stem cells (ESCs), which are derived from early-stage embryos - destroying the embryo in the process - iPSCs are generated from adult tissues like skin or blood. This completely sidesteps ethical concerns. While adult stem cells, such as those found in bone marrow, also avoid ethical issues, they are multipotent, meaning they can only develop into a limited range of cell types related to their tissue of origin.

Both iPSCs and ESCs share a critical ability: pluripotency. This means they can transform into any of the 200+ cell types in the human body, from neurons to heart cells to pancreatic tissue. Adult stem cells, however, lack this flexibility. Another major advantage of iPSCs is their potential for personalized medicine. Since they can be created from a patient’s own cells, they carry the same genetic code, which significantly reduces the risk of immune rejection - a common issue with ESCs derived from unrelated donors.

However, iPSCs come with their own safety challenges. The reprogramming process involves genes like c-Myc, which is linked to cancer. Early studies found that 25% of mice transplanted with certain iPSCs developed lethal tumors.

"Induced pluripotent stem cells have given us a window into human development unlike anything we had before."

As Arnold Kriegstein, MD, PhD, Director of UCSF's Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, explained, researchers are continually refining the process to reduce these risks while maintaining the extraordinary potential of iPSCs.

Medical Applications of iPSCs

Disease Modeling and Drug Development

iPSCs have revolutionized the way scientists study diseases and develop treatments by enabling the creation of in-vitro disease models. These models eliminate the need for animal testing, which often fails to replicate human-specific disease mechanisms. For example, researchers can reprogram a patient’s cells into neurons, cardiomyocytes, or other tissue types that are typically inaccessible, providing a direct window into conditions like Parkinson’s disease, which affects about 1% of people over 60.

A notable example is a Phase I/II trial (jRCT2090220384) conducted at Kyoto University between 2018 and 2024, led by Jun Takahashi. In this study, scientists transplanted iPSC-derived dopaminergic neurons into seven Parkinson’s patients. Results published in April 2025 showed that the transplanted cells survived, produced dopamine, and improved motor function without causing tumors. Additionally, combining iPSC technology with CRISPR gene editing allows researchers to create isogenic cell pairs, which help pinpoint the effects of specific mutations. These advancements naturally pave the way for regenerative therapies, where iPSCs are used to repair damaged tissues.

Tissue Repair and Transplantation

iPSCs hold immense potential for repairing tissues damaged by injury or disease. For instance, a heart attack can destroy up to 1 billion cardiomyocytes in the left ventricle. iPSC-derived heart cells offer a promising solution to regenerate this lost tissue. In October 2024, researchers at Tianjin First Center Hospital in China achieved a breakthrough by reprogramming a patient’s adipose-derived mesenchymal stromal cells into iPSCs. These were then differentiated into insulin-producing islets and transplanted under the abdominal muscle. Remarkably, within a year, the patient achieved full insulin independence with an HbA1c level of about 5%.

Between 2019 and 2021, Osaka University explored the use of iPSC-derived corneal epithelial sheets to treat four patients with limbal stem cell deficiency. Over two years, the procedure improved vision and reduced corneal cloudiness, with no serious adverse effects. Tissue patches and 3D organoids derived from iPSCs also provide better structural support and cell retention - often exceeding 10% - compared to single-cell injections, which typically retain only 1–10% of transplanted cells.

Personalized Medicine and Treatment Options

One of the most exciting aspects of iPSCs is their ability to transform personalized medicine. Since iPSCs are created from a patient’s own cells - whether from skin, blood, or urine - they carry the same genetic makeup, drastically lowering the risk of immune rejection and eliminating the need for long-term immunosuppressive drugs. This also allows researchers to test various treatments on the patient’s derived cells to identify the most effective and least harmful options.

"This is a completely different way of looking at medicine - replacing diseased cells rather than drugging them. And we're right on that precipice."
– Seth Ettenberg, CEO, BlueRock Therapeutics

To make treatments more accessible, donor-derived iPSC banks have significantly cut costs, now requiring only about one-fifth of the expenses associated with autologous therapies. Researchers are also using CRISPR to engineer "hypoimmune" iPSCs by deleting HLA molecules, enabling transplanted tissues to evade the immune system without the need for heavy immunosuppression. These advancements highlight the potential of iPSCs to deliver tailored therapeutic solutions, marking a new era in regenerative and personalized healthcare.

Benefits of iPSCs Over Other Stem Cells

Ethical Sourcing and Accessibility

Induced Pluripotent Stem Cells (iPSCs) sidestep the ethical dilemmas tied to embryonic stem cells (ESCs) by using readily available adult cells like skin, blood, or even urine. This eliminates the need for embryo destruction, which has been a significant ethical barrier for ESC research in many parts of the world. By avoiding these concerns, iPSCs pave the way for more personalized and widely accepted regenerative treatments.

"The central ethical advantage of iPSCs is that they do not require the destruction of embryos."
– Naeem Arifa, Department of Microbiology, University of London

On top of addressing ethical concerns, iPSCs are easier to source. Unlike ESCs, which depend on scarce donated embryonic tissue, iPSCs can be generated from simple and minimally invasive procedures, such as drawing blood or taking a skin biopsy. Advances in technology now allow researchers to create iPSCs from as little as 50–100 μL of blood - just a few drops - making it possible to produce these cells on demand for clinical applications.

Lower Risk of Immune Rejection

The benefits of iPSCs go beyond ethical considerations. Since these cells can be derived from a patient’s own tissue, they are a perfect genetic match. This personalized approach drastically reduces, or even eliminates, the risk of immune rejection - a persistent issue with ESCs, which often require immunosuppressive drugs when sourced from donors. Avoiding these drugs spares patients from their potential side effects, including increased vulnerability to infections and organ damage.

"It is clear that stem cells that are identical to your own are the best... the body does not initiate a process of rejection against them."
– Mahendra S. Rao, MD PhD, Consultant in Regenerative Medicine

A striking example of this advantage comes from a 2017 study led by ophthalmologist Masayo Takahashi at RIKEN in Japan. Retinal cells derived from patients’ own iPSCs were implanted into two individuals with macular degeneration. These cells survived for over a year without any sign of rejection. Furthermore, researchers in Japan have identified "super donor" iPSC lines - cells with HLA types that match a significant portion of the population. One such line could potentially match 17% of people, offering a way to treat many without the need for additional immunosuppression.

iPSCs vs. Embryonic Stem Cells: A Comparison

Feature	Induced Pluripotent Stem Cells (iPSCs)	Embryonic Stem Cells (ESCs)
Source	Derived from adult cells (skin, blood, urine)	Taken from the inner cell mass of a blastocyst
Ethical Concern	Minimal; no embryos destroyed	High; requires embryo destruction
Immune Rejection	Low (if patient-specific)	High (requires immunosuppression)
Genetic Match	Can be 100% identical to the patient	Not patient-specific
Potency	Pluripotent	Pluripotent
Accessibility	High; uses abundant tissues	Limited; relies on donated tissue
Tumor Risk	Potential for teratomas if undifferentiated	Potential for teratomas if undifferentiated

While both iPSCs and ESCs share the ability to transform into any cell type, iPSCs stand out for their ethical sourcing, compatibility with patients, and ease of access. These groundbreaking advantages earned Shinya Yamanaka and John Gurdon the Nobel Prize in Physiology or Medicine in 2012, marking a major milestone in regenerative medicine. By addressing ethical challenges and improving clinical safety, iPSCs have become a cornerstone of modern medical research and treatment.

Stem Cell Banking and Americord Registry

Banking Cord Blood and Tissue for Future iPSC Use

Newborn stem cell banking plays a key role in the development of iPSC-based regenerative therapies. Banked cells serve as the foundation for future personalized treatments. Cord blood stem cells, often called "immunologically pristine", are collected under strict standards, making them ideal for iPSC generation. Unlike adult cells, which can accumulate environmental damage over time, cord blood cells are collected at birth, offering a cleaner and more reliable starting material.

"Scientists have shown that cord blood cells are a very good starting material for making iPSC. Cord blood stem cells are immunologically pristine, are collected in the correct manner for a cell therapy starting material, have regulatory approval for many indications, and in the public cord blood banks they are already HLA typed."
– Mahendra S. Rao, MD PhD, Consultant in Regenerative Medicine

What makes this even more exciting is how efficiently iPSCs can be generated from a small portion of banked cord blood. These cells are self-renewing, meaning a tiny sample can create enough cells for multiple therapies throughout a lifetime, while the majority of the original sample stays safely stored.

"If a small portion of the cord blood was used to make iPSC, while the bulk was banked as usual, then the additional cells generated on the iPSC pathway could provide for multiple additional therapies from the original cord blood donor."
– Mahendra S. Rao, MD PhD, Consultant in Regenerative Medicine

Americord Registry has embraced this potential with advanced banking and processing methods. Their CryoMaxx™ processing preserves tissues as intact sheets, maintaining higher levels of growth factors, cytokines, and multipotent cells - all essential for future therapies and iPSC generation. Stored at -196°C, these cells can remain viable for over 200 years, ensuring long-term usability.

Americord Registry's Service Plans

Americord Registry offers a variety of service plans to help families safeguard these valuable biological resources for future regenerative treatments. Their five plans provide options to bank multiple types of stem cells, all of which could play a role in iPSC-based therapies.

Americord Service Plan	Included Services	Potential iPSC/Regenerative Use
Essential Family Plan	Cord Blood Banking, CryoMaxx™ Processing	Source for blood-lineage iPSCs
Advanced Family Plan	Cord Blood + Cord Tissue Banking	Includes hematopoietic and mesenchymal stem cells for tissue repair
Complete Family Plan	Cord Blood + Cord Tissue + Placental Tissue Banking	Offers access to cells with natural pluripotency markers
Ultimate Family Plan	All of the above + Newborn Exosome Banking	Adds cellular messengers to enhance regenerative potential
Maximum Family Plan	All services + Maternal Exosome Banking	Provides the most extensive biological safety net for families

The Complete Family Plan and higher tiers stand out for iPSC applications due to the variety of cell types they secure. Cord blood provides hematopoietic and mesenchymal stem cells and epithelial cells. This diversity opens up multiple pathways for generating iPSCs that can regenerate blood cells, repair damaged tissues, or address neurological conditions - all while maintaining the cellular quality needed for successful therapies.

Americord Registry is AABB accredited, FDA registered, and offers a $110,000 engraftment guarantee to ensure an alternative source is available if a banked cord blood unit fails during a transplant. With over 80 FDA-approved treatments already using newborn stem cells and the likelihood that 1 in 3 individuals could benefit from regenerative medicine, banking these cells offers families a proactive way to prepare for both current and future healthcare advancements.

Wrapping Up

The potential of regenerative medicine using iPSCs is becoming increasingly tangible. These reprogrammed adult cells bring an extraordinary level of adaptability to therapies, with recent medical advancements showcasing their ability to address conditions once thought untreatable.

One of the key advantages of iPSCs is their autologous nature, which significantly reduces the risk of immune rejection. This eliminates the need for lifelong immunosuppressive drugs, making treatments safer and more tailored to individual patients. It's this level of personalization that makes iPSCs a standout in the evolving field of medicine.

Stem cell banking plays a crucial role in this future. By storing cord blood and tissue at birth, families can preserve young, undamaged cells that are ideal for future iPSC-based treatments. These pristine cells, free from the wear and tear of aging or environmental exposure, provide a solid starting point for the therapies of tomorrow.

The groundbreaking work of Shinya Yamanaka, which earned him the Nobel Prize in 2012, is now moving from theory to practice. Partnering with a trusted provider like Americord Registry ensures families are prepared for these advancements. With AABB-accredited facilities, CryoMaxx™ processing, and robust service plans, Americord offers a reliable way to safeguard cellular resources for the future.

"The stem cell field is very young. And there is a fantastic future for it."

This quote from Constantinos Chronis of the University of Illinois Chicago underscores the importance of acting today. Banking young, healthy cells now lays the groundwork for accessing the transformative potential of regenerative medicine in the years ahead.

FAQs

Are iPSC treatments available in the U.S. today?

Yes, iPSC-based therapies are making progress in the U.S., with some already in clinical trials. Notably, the first therapy derived from iPSCs has reached Phase III trials as of February 2025. This milestone represents a major advancement in the journey toward broader availability of iPSC treatments.

How do scientists prevent iPSCs from forming tumors?

Scientists work to lower the risk of tumors in induced pluripotent stem cells (iPSCs) by tightly managing their culture conditions and applying precise genetic reprogramming techniques. These approaches reduce the chances of harmful mutations, helping to prevent cancerous growths and ensuring the cells are safe for medical applications.

Why bank cord blood now if iPSCs can be made from adult cells?

Banking cord blood is valuable because its stem cells are readily available, extensively researched, and have proven success in treating specific blood disorders and cancers. While induced pluripotent stem cells (iPSCs) hold potential for future treatments, they remain experimental and are not yet widely applied. Cord blood stem cells, being a perfect genetic match for the child, provide a dependable and accessible option for both current and potential medical needs.